ContactContact
Des avancées qui changent la vie des patients

Nos dernières actus

Example

Quels que soient les défis à relever, la Science vaincra.

Pour la première fois en France, Pfizer lance une campagne d’image grand public autour d’un film signature diffusé au cinéma et en ligne.

Voir la vidéo DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Inscrivez-vous à la 16ème édition du Forum Patient Pfizer et découvrez le programme.

Cette année, c’est Objectif Résilience ! 


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Pfizer célèbre la Science dans sa nouvelle campagne

Luca Mollo, vice-président et directeur médical de Pfizer, revient sur les raisons d'une telle confiance dans la Science.


En savoir plus

La Science vaincra

Depuis la création de Pfizer en 1849, nous nous sommes appuyés sur la science pour faire reculer ou vaincre la maladie.


En savoir plus

Pfizer et WILCO lancent la 4ème édition du Pfizer Healthcare Hub France

L’appel à candidatures est ouvert aux startups françaises innovantes en santé du 5 au 29 septembre 2023.


En savoir plus

Notre modèle de l’open innovation, en France, au service des patients !

Une seule stratégie : créer des alliances à impact.


En savoir plus

Choose France

Pfizer porte à plus d'un milliard d'euros son investissement pour soutenir la recherche et l'innovation en santé.


En savoir plus

La diversité ethnique et les essais cliniques, où en est-on ?

Le sexe, l’âge et l’origine raciale ou ethnique peuvent tous avoir un impact sur la façon dont différentes personnes répondent au même médicament ou vaccin.


En savoir plus

« Lightspeed », une méthode pour le futur de la santé ?

Pour les patients, l’industrie biopharmaceutique n’a pas d’autre choix que de passer à une autre échelle.


En savoir plus

Pfizer, une entreprise responsable engagée dans le monde entier

Découvrez les principaux engagements environnementaux et sociétaux de Pfizer


En savoir plusCommuniqués de presse

24 novembre 2023
Pfizer récompense quatre projets d’associations de patients lors de son Forum Patient 2023 sur la résilience du système de santé

13 octobre 2023
Vivre avec la migraine : une équation difficile entre gestion des crises et vie familiale, sociale et professionnelle

En savoir plusNous contacterRetrouvez ici les différents numéros, adresses et liens utiles pour nous contacter selon votre besoin : information médicale, pharmacovigilance, commandes, Autorité de Santé…En savoir plusNotre R&D en FranceEn France, notre modèle de R&D est ouvert aux partenariats, qu’ils soient académiques ou noués avec des sociétés de biotechnologie.En savoir plus
MédicamentsProfessionnels de santéConseils et préventionMédias Actus Aires thérapeutiquesR&DEngagementsNous connaîtreTravailler chez PfizerConditions générales d'utilisation Cookies Données personnelles ContactPP-GIP-FRA-1849
Copyright © 2022 Pfizer inc. Tous droits réservés. Le contenu de ce site est destiné aux personnes résidant en France.
MédicamentsProfessionnels de santéConseils et préventionMédias Actus Aires thérapeutiquesR&DEngagementsNous connaîtreTravailler chez PfizerConditions générales d'utilisation Cookies Données personnelles ContactPP-UNP-FRA-1121
Copyright © 2023 Pfizer inc. Tous droits réservés. Le contenu de ce site est destiné aux personnes résidant en France.